Hyperalgesia: When Pain Hurts More Than It Should

Hyperalgesia and allodynia are often discussed together, and they do share a common underlying mechanism in central sensitization. But they are distinct phenomena, and the distinction matters for understanding what the nervous system is doing in fibromyalgia [1].

Allodynia is pain from a stimulus that should not hurt at all: a light touch, a gentle breeze, the weight of a bedsheet. Hyperalgesia is an amplified pain response to a stimulus that is genuinely painful: a bump, a pinch, a firm squeeze. The stimulus activates pain receptors appropriately, but the resulting pain is disproportionate to what the stimulus warrants. A bump that should produce a brief “ow” produces a sharp, intense, lingering pain. The IASP defines hyperalgesia as “increased pain from a stimulus that normally provokes pain” [1].

The difference is not academic. Allodynia involves a reclassification: touch fibers carrying non-painful information get processed as pain in the spinal cord. Hyperalgesia involves an amplification: pain fibers carrying a legitimate pain signal have that signal multiplied at the spinal or supraspinal level, producing a response that is larger in magnitude, longer in duration, or both. Both phenomena are measurable in the laboratory, both are features of central sensitization, and both are prominent in fibromyalgia. But they tell different stories about what the nervous system is doing, and understanding that distinction is part of understanding why fibromyalgia produces the symptom profile it does.

Primary and Secondary Hyperalgesia

The distinction between primary and secondary hyperalgesia reveals where in the nervous system the amplification is happening, and it is one of the clearest pieces of evidence that central sensitization is a real, localizable biological phenomenon [2].

Primary hyperalgesia occurs at the site of tissue damage. When you burn your finger, the area around the burn becomes more sensitive to pain for hours or days. This is driven primarily by peripheral sensitization: inflammatory mediators at the injury site (prostaglandins, bradykinin, substance P, nerve growth factor) lower the threshold of local pain receptors and increase their response magnitude. This is normal protective biology: heightened sensitivity around an injury makes you careful with the damaged tissue while it heals. Primary hyperalgesia resolves as the tissue heals and the peripheral sensitization subsides.

Secondary hyperalgesia occurs in tissue surrounding the injury that is not itself damaged. The area around the burn, extending centimeters beyond the injured tissue, becomes sensitive to pinprick stimuli. This cannot be explained by peripheral sensitization, because the surrounding tissue is not inflamed. Secondary hyperalgesia is produced by changes in the spinal cord: central sensitization of dorsal horn neurons causes them to amplify signals from the uninjured tissue [2]. Latremoliere and Woolf described the molecular mechanisms in detail: repeated input from C-fibers at the injury site causes long-term potentiation of synaptic transmission in the dorsal horn, NMDA receptor activation strengthens the response of central neurons to subsequent inputs, and the receptive fields of those neurons expand, meaning they now respond to input from areas of skin they previously did not cover.

The critical observation is that secondary hyperalgesia is selectively sensitive to mechanical stimuli (pinprick, pressure) but not to heat. This selectivity is a signature of central, not peripheral, sensitization: if the surrounding tissue were inflamed, heat hyperalgesia would be present as well.

In fibromyalgia, the hyperalgesia is widespread rather than localized around an injury, which places it firmly in the category of centrally mediated amplification. Staud and colleagues demonstrated that both mechanical and heat hyperalgesia in fibromyalgia patients correlated with clinical pain intensity, suggesting that the same central amplification mechanism driving the experimental finding is driving the everyday pain experience [3]. The presence of heat hyperalgesia as well as mechanical hyperalgesia in fibromyalgia suggests that the sensitization involves both spinal and supraspinal mechanisms, a more extensive pattern than what is seen around a simple peripheral injury.

What the Brain Studies Show

Gracely and colleagues used functional MRI to directly observe hyperalgesia in fibromyalgia [6]. They applied pressure stimuli to fibromyalgia patients and controls. When they matched the stimuli by objective pressure intensity, fibromyalgia patients showed dramatically greater activation in pain-processing brain regions, including the primary and secondary somatosensory cortices, the insula, and the anterior cingulate cortex. When they matched by subjective pain rating (applying less pressure to fibromyalgia patients until they reported the same pain level as controls receiving stronger pressure), the brain activation patterns were similar.

This finding is among the most important in fibromyalgia research, and it is worth understanding precisely what it demonstrates. The fibromyalgia brain is not responding normally to a stimulus and then catastrophizing about it; it is producing a genuinely larger neural response to the same input. When the subjective experience is matched, the brain activity matches. This means the amplification is happening before the conscious experience of pain, not as a psychological overlay on top of it. The patient who says “this hurts more than it should” is accurately reporting what their nervous system is doing.

The study also addresses, albeit indirectly, the persistent suspicion that fibromyalgia patients are exaggerating. If the neural response to a given pressure stimulus is objectively larger in fibromyalgia, the higher pain ratings are an accurate report of a larger neural event. The pain is real, the amplification is real, and the imaging evidence places the mechanism in the brain’s pain-processing circuits, not in the patient’s willingness to report truthfully.

Hyperalgesia Across Conditions

Hyperalgesia is not unique to fibromyalgia. Lee and colleagues reviewed the evidence across rheumatic conditions and found that central pain amplification, measured by hyperalgesia to experimental stimuli, is present in rheumatoid arthritis and osteoarthritis as well as fibromyalgia [4]. The degree of hyperalgesia in these conditions correlates with symptom severity independently of inflammatory markers or structural damage, suggesting that central sensitization contributes to pain in these conditions above and beyond the peripheral pathology.

This finding has practical implications that extend well beyond fibromyalgia. A patient with osteoarthritis whose pain is disproportionate to their imaging findings may have a central sensitization component. Treating only the peripheral joint pathology while ignoring the central amplification will produce incomplete results. Joint replacement surgery, for instance, resolves the peripheral source of nociceptive input, but if the central sensitization is not addressed, the patient may continue to experience amplified pain from other inputs, or may develop chronic postsurgical pain. Preoperative assessment of central sensitization, including measures of hyperalgesia, is beginning to be studied as a predictor of surgical outcomes for this reason.

Opioid-Induced Hyperalgesia

A particularly important form of hyperalgesia occurs paradoxically from opioid use. Opioid-induced hyperalgesia (OIH) is a state in which opioid treatment increases pain sensitivity rather than reducing it [5]. The mechanisms include upregulation of NMDA receptor activity, activation of descending facilitation pathways from the rostral ventromedial medulla, and changes in spinal cord processing that mirror some of the changes seen in fibromyalgia.

OIH is clinically distinct from opioid tolerance, though the two can be difficult to distinguish at the bedside. Tolerance means the same dose produces less analgesia, requiring a higher dose to maintain pain relief. OIH means the opioid is actively increasing pain sensitivity: the patient is in more pain because of the opioid, not despite it. The clinical clue is that in tolerance, increasing the dose provides temporary relief, while in OIH, increasing the dose can paradoxically worsen the pain. The definitive test, where possible, is dose reduction: if pain improves when the opioid dose is lowered, OIH is the more likely explanation.

OIH is clinically relevant because opioids have historically been prescribed for fibromyalgia, despite limited evidence for benefit. If opioid use can worsen the very type of central sensitization that drives fibromyalgia, the argument against routine opioid use in this condition becomes mechanistic as well as empirical. Current guidelines generally recommend against opioids for fibromyalgia, and OIH is one of the reasons [5].

What Remains Uncertain

Whether hyperalgesia in fibromyalgia is a stable trait or fluctuates with symptom severity is not well established by longitudinal data. Cross-sectional studies capture a snapshot, but fibromyalgia symptoms fluctuate, and whether the degree of hyperalgesia tracks those fluctuations or remains relatively constant through flares and remissions has not been adequately studied over time. Whether the degree of hyperalgesia (measured by quantitative sensory testing) predicts treatment response to specific interventions is an active research question; if it does, it could allow clinicians to match treatments to individual patients based on their sensory profile.

The relative contributions of peripheral input (ongoing nociceptive signals from muscles and joints) versus purely central mechanisms in maintaining hyperalgesia in fibromyalgia are debated, and the answer likely varies between individuals. Some evidence suggests that peripheral nerve pathology, including small fiber neuropathy, may contribute to the ongoing input that maintains central sensitization in a subset of fibromyalgia patients. If confirmed, this would have treatment implications, because interventions targeting peripheral input would have a different rationale than interventions targeting purely central mechanisms.

And whether exercise, which is the most consistently effective intervention for fibromyalgia, reduces pain partly by directly modifying hyperalgesia at the spinal cord level (exercise-induced hypoalgesia) or primarily through other mechanisms, such as improved sleep, reduced stress, or activation of endogenous opioid systems, is an area where the evidence is suggestive but incomplete.

Getting support for chronic pain. Chronic pain, including fibromyalgia, is a complex medical condition that deserves proper clinical attention. A GP, rheumatologist or pain specialist can help develop a management plan. The American Chronic Pain Association (theacpa.org) and the National Fibromyalgia Association (fmaware.org) have patient resources and practitioner directories.